J&J Says Tremfya (Guselkumab) Long-Term Data Show Sustained Clinical And Endoscopic Remission In Ulcerative Colitis Through 3 Years
ReutersFeb 21, 2026 1:01 PM
Feb 21 (Reuters) - Johnson & Johnson JNJ.N:
J&J - TREMFYA (GUSELKUMAB) LONG-TERM DATA SHOW SUSTAINED CLINICAL AND ENDOSCOPIC REMISSION IN ULCERATIVE COLITIS THROUGH 3 YEARS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Nikkei Index Heading Toward 60,000? Why Is Global Capital Betting on Sanae Takaichi? Will Japan’s Stock Market Continue to Hit New Highs in 2026?
TradingKey - In February 2026, the Tokyo stock market once again became the epicenter of global financial markets. Following a landslide victory by the Sanae Takaichi-led Liberal Democratic Party in the Lower House elections, the Nikkei 225 Index hit consecutive record highs within just a few days, targeting the 60,000-point milestone.TradingKey
7 hours ago
Beyond Gold, What Is the Next Safe-Haven Asset Choice?
TradingKey - Against the backdrop of heightened global market volatility, escalating geopolitical risks, and mixed macroeconomic signals, market safe-haven sentiment continues to intensify. In the face of rising uncertainty, an increasing number of investors are seeking safe havens capable of wealth preservation and risk mitigation.TradingKey
11 hours ago
Will Micron Be the 2026 AI Winner as the Memory Supercycle Begins?
Recently, Micron has focused on premium areas such as High-Bandwidth Memory that plays alongside accelerators to feed AI models, and adding capacity with an eye on pricing discipline.TradingKey
15 hours ago
